People | December 06, 2022
Biocon Biologics elevates Shreehas Tambe as MD & CEO
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy
The only definitive way to diagnose and stage lung cancers is through biopsies
Total investment envisaged in this project stands at up to Rs 70 crore
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
It will undertake academic and collaborative research activities in Ayurveda, including herbal medicine and yoga, as well as design academic standards, short-term/medium-term courses, and educational guidelines
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Subscribe To Our Newsletter & Stay Updated
